Business Context and Reporting Period
This Form 8-K Current Report, dated October 2, 2013, covers events reported by Harvard Bioscience, Inc. (HBIO) regarding executive leadership changes and a planned corporate restructuring. The report details the appointment of a new Chief Financial Officer and the Board's approval of a spin-off of its subsidiary, Harvard Apparatus Regenerative Technology, Inc. (HART).
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for the reporting period. The document focuses on executive compensation terms and the mechanics of a corporate distribution rather than operational financial results.
- Executive Compensation: Robert E. Gagnon's annual base salary is set at $290,000.
- Incentive Compensation: Eligible for annual cash incentives up to 50% of base salary based on objectives including EPS, revenue growth, and cash flow as a percentage of EBITDA.
- Equity Grant: An option to acquire 150,000 shares of common stock is scheduled for grant following the HART spin-off, vesting over four years.
Material Changes
The filing reports two material changes to the company's structure and leadership:
- Executive Departure and Appointment: Thomas McNaughton is departing as CFO. Robert E. Gagnon was appointed Executive Vice President – Finance, with a transition to CFO following the HART spin-off. His employment commenced October 23, 2013.
- Corporate Spin-off: The Board approved the distribution of all common stock of HART to HBIO shareholders. The distribution is expected on November 1, 2013, to shareholders of record as of October 21, 2013.
- Distribution Ratio: Shareholders will receive one share of HART common stock for every four shares of HBIO common stock held.
Guidance, Outlook, and Risks
The filing outlines the timeline for the HART spin-off and the terms of the new CFO's employment agreement, including severance provisions. No specific financial guidance or forward-looking revenue projections are provided in this text.
- Severance Terms: If terminated without cause, Mr. Gagnon is entitled to 12 months of base salary. In the event of a Change in Control, termination triggers a lump sum payment of 12 months' salary and immediate acceleration of stock options.
- Contingencies: The grant of the 150,000 share option is contingent upon the completion of the HART spin-off. If Mr. Gagnon terminates employment before the grant, he may receive a cash payment equal to the Black-Scholes value of the option under certain circumstances.
Investor Verification Checklist
- Verify the record date of October 21, 2013, to determine eligibility for the HART stock distribution.
- Confirm the exact distribution date of November 1, 2013, for the HART spin-off.
- Review the full Employment Agreement (Exhibit 10.1) for detailed definitions of "Cause" and "Change in Control."
- Check the Preliminary Information Statement (Exhibit 99.3) for details on HART's business and management.
- Monitor the transition of CFO duties from Thomas McNaughton to Robert E. Gagnon post-spin-off.